Based on results from GWAS studies, the IL-23/Th17 axis is considered to be the most important driver of psoriasis [100,101], with several clinical trials revealing the efficacy of current IL-23 and IL-17 inhibitors in use [102]. Here, IL23A is linked to psoriasis.